Program Schedule

1055
Antibody Response to Intradermal and High Dose Influenza Vaccine in 2012-13 Among Adults Who Did and Did Not Respond to Standard Dose Vaccine in 2011-12

Session: Poster Abstract Session: Vaccines: Influenza
Friday, October 10, 2014
Room: The Pennsylvania Convention Center: IDExpo Hall BC
Posters
  • IDWeek_OptC12_2014.pdf (107.8 kB)
  • Background: We compared antibody responses to influenza vaccine in adults ≥50 years old in two consecutive seasons. In 2011-12, all participants received trivalent inactivated influenza vaccine (IIV3). In 2012-13, those age 50-64 received intradermal (ID) and those age ≥65 received high-dose vaccine (HD). In 2012-13, the WHO-recommended vaccine strains were modified for H3N2 and B.

    Methods: Participants were recruited in 2011 and vaccinated in the fall of 2011 and 2012. In both years, pre- and post (21-28 days)-vaccination sera were tested for antibody response to vaccine [measured by hemagglutination inhibition (HI) titer]. We compared geometric mean titers (GMT) and titer fold rise from pre- to post-vaccination in 2012, among 2011-12 responders (≥4-fold rise in HI titer from pre-to post-vaccination) and 2011-12 non-responders (<4-fold rise in HI titer) to the corresponding vaccine strain.

    Results: 183 adults received IIV3 in 2011 and either HD (N = 82) or ID (N = 101) in 2012. For the 2011-12 vaccine, 56 (31%) responded to the H1N1 strain, 68 (37%) responded to H3N2, and 28 (15%) responded to B. Among HD recipients, post-vaccination GMT for H3N2 was higher among 2011-12 responders vs. non-responders (p = 0.04). Fold rise did not differ significantly for any vaccine strains between responders vs. non-responders.

    HD recipients

    ID recipients

    Strain

    2012-13 Response

    2011-12

    Non-responders

    2011-12 Responders

    2011-12

    Non-responders

    2011-12 Responders

    H1N1

    Post-vaccination GMT (IQR)

    93 (57, 160)

    128 (80, 320)

    78 (40, 226)

    105 (40, 160)

    Median fold rise (IQR)

    4 (2, 8)

    4 (1, 8)

    2 (1, 4)

    2 (2, 4)

    H3N2

    Post-vaccination GMT (IQR)

    154 (80, 320)*

    242 (160, 452)

    120 (57, 320)

    118 (40, 226)

    Median fold rise (IQR)

    4 (2, 8)

    4 (2, 11)

    2 (1, 4)

    2 (1, 8)

    B

    Post-vaccination GMT (IQR)

    185 (80, 320)

    180 (80, 320)

    137 (80, 320)

    163 (80, 320)

    Median fold rise (IQR)

    3 (1, 8)

    2 (2, 11)

    2 (1, 6)

    3 (1, 16)

    * p < 0.05 for comparison of 2011-12 responders and non-responders.

    Conclusion: Prior response to 2011-12 vaccine antigen was not associated with response to the new H3N2 or B antigens in 2012-13, nor was it associated with response to the H1N1 antigen used in both the 2011-12 and 2012-13 vaccines.

    Maria Sundaram, MSPH1, Huong Mclean, MPH, PhD1, Jennifer Meece, PhD2, Richard K. Zimmerman, MD MPH3, Mary Patricia Nowalk, PhD3, Chyongchiou J Lin, PhD3, Thomas Friedrich, PhD4, Sarah Spencer, Ph.D.5 and Edward Belongia, MD1, (1)Center for Clinical Epidemiology and Population Health, Marshfield Clinic Research Foundation, Marshfield, WI, (2)Integrated Research and Diagnositic Laboratory, Marshfield Clinic Research Foundation, Marshfield, WI, (3)Family Medicine, University of Pittsburgh, Pittsburgh, PA, (4)Pathobiological Sciences, University of Wisconsin School of Veterinary Medicine, Madison, WI, (5)Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA

    Disclosures:

    M. Sundaram, MedImmune, LLC: Project scientist on MedImmune-funded grant, Research grant

    H. Mclean, MedImmune, LLC: Grant Investigator, Research grant

    J. Meece, None

    R. K. Zimmerman, Sanofi: Grant Investigator, Research grant
    Pfizer: Grant Investigator, Research grant

    M. P. Nowalk, Sanofi: Grant Investigator, Research support
    Pfizer: Grant Investigator, Research support
    Merck: Grant Investigator, Research support
    MedImmune: Consultant, Consulting fee

    C. J. Lin, MedImmune, LLC: Consultant, Consulting fee
    Sanofi Pasteur: Grant Investigator, Research grant
    Merck: Grant Investigator, Research grant

    T. Friedrich, None

    S. Spencer, None

    E. Belongia, MedImmune, LLC: Grant Investigator, Research grant

    See more of: Vaccines: Influenza
    See more of: Poster Abstract Session

    Findings in the abstracts are embargoed until 12:01 a.m. EDT, Oct. 8th with the exception of research findings presented at the IDWeek press conferences.

    Sponsoring Societies:

    © 2014, idweek.org. All Rights Reserved.

    Follow IDWeek